Achievements

European Pharmacopoeia Commission members and observers (2023)

39 member states
31 observers
New observers in 2023: Egypt and the Kyrgyz Republic

Europe

39 member states
5 observer states

North America

3 observer states

South America

2 observer states

Africa

8 observer states

Asia

10 observer states

Oceania

1 observer state

Non-state

EU (member)*
TFDA and WHO (observers)*

*EU: European Union. TFDA: Taiwan Food and Drug Administration. WHO: World Health Organization.

Quality & use of medicines

European Pharmacopoeia

new monographs
0
new general chapters
0
revised texts
0

Selected European Pharmacopoeia texts adopted in 2023

  • One new general chapter: Comparability of alternative analytical procedures (5.27)

  • Two new monographs: Cannabis flower (3028) and Cannabidiol (3151)

Biological Standardisation Programme achievements

Total number of projects

21

Concluded projects

6

Projects still running

15

Standard Terms Database key figures

Registered users

43 000

Individual standard terms concepts

1 076

Entries

31 500

Languages

35

European Paediatric Formulary

PaedForm Online Platform

new users
0
registered users
0

Activities

Laboratory verification conducted prior to public consultation in 2023, in line with the adapted procedure, for:

  • Chloral hydrate 100 mg/mL oral solution (F0010),
  • Clonidine hydrochloride 10 µg/mL oral solution (F0018),
  • Furosemide 2 mg/mL oral solution (F0003).

The first text was published in the European Paediatric Formulary in October 2023, while the two others are pending adoption by the CD-P-PH.

The PaedF Working Party decided to routinely verify the test methods and the microbiological quality of preparations, where relevant. By confirming the microbiological quality of formulations, in addition to their chemical stability, the European Paediatric Formulary can provide additional backing to unlicensed formulations.

Work Programme 2023

  • Amiodarone hydrochloride capsules
  • Amiodarone oral solution
  • Baclofen oral suspension
  • Chloral hydrate rectal solution
  • Clonidine hydrochloride oral solution
  • Ethambutol hydrochloride oral solution
  • Flecainide acetate oral solution
  • Furosemide oral solution
  • Isoniazid oral solution
  • Lorazepam oral solution
  • Nifedipine oral liquid
  • Pyrazinamide oral suspension
  • Simple syrup (with preservatives)
  • Valaciclovir hydrochloride oral solution

Possible next candidates for addition to the work programme:

  • Amlodipine oral liquid
  • Phenytoin oral liquid
  • Pyridoxine oral suspension
  • Spironolactone oral suspension

Reference standards

new RSs
0
replacement RS batches adopted
0
countries to which EDQM RSs are distributed directly
0
RSs available
0
RS portfolio availability ensured
> 0 %
vials produced
0
batches produced
0

Certification of suitability to the European Pharmacopoeia monographs (CEP)

Total valid and issued CEPs in 2023

442

new certificates

1 416

revised certificates

6 310

valid certificates

In 2023 there was a slight reduction in new certificates (down 4%) and revised certificates (down 8%). 

There were also a total of 2 400 requests for revision of CEPs (up 10%) and 381 new applications (down 10%).

Finally, the following inspections were conducted in 2023: 26 on-site, 2 RTEMIS and 35 desktop assessments.

Network of Official Medicines Control Laboratories (OMCLs)

total participating OMCLs
0
representing EU member states
0
from non-EU states
0
MJAs
0
PTS studies
0
TV/tutorials
0

EU/EEA specific activities in 2023

CAP programme
0
MRP/DCP programme (registered projects)
0
Surveillance of biologicals for human use (vaccines, blood and plasma pools)
0

Substances of human origin

Organs, tissues and cells

designated national focal points (NFPs)
0
Information from almost 900 patients included in the Registry of International Travel for Transplantation Activity (RITTA)
0

Blood transfusion

B-PTS studies conducted
0
participating laboratories (on average, per study)
0

Nucleic amplification technique (NAT)

  • B-PTS068 HBV/HCV/HIV NAT

Serology

  • B-PTS069 Anti-HCV
  • B-PTS070 HBsAg/Anti-HBc
  • B-PTS071 Anti-Treponema
  • B-PTS072 Anti-HIV/p24

Immuno-haematology

  • B-PTS073 ABO, Rhesus, extended phenotyping and irregular antibodies

Pharmaceuticals and Pharmaceutical Care

0

recommendations on the classification of medicines and their supply conditions (prescription and non-prescription status) established by the CD-P-PH/PHO and entered into the Melclass database.

Quality management system

Quality management remains a high priority for the EDQM. In 2023, the EDQM maintained its ISO 9001:2015 certificate following audits from the certification body in February 2023 and in December 2023. In addition, the ISO 17025:2017 accreditation certificate was maintained by the accreditation body following the second surveillance audit held in May 2023. Twenty-one of the EDQM Laboratory’s techniques are covered by this certificate.

The EDQM makes all necessary efforts to continually develop and improve its quality management system. Its customers and interested parties can therefore have faith in the consistent quality of the goods and services provided by the EDQM.